norovirus

dart board miss failure
Biotech

HilleVax stock sinks 80% after norovirus vaccine flunks phase 2

HilleVax's stock took a nosedive after its sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis.
James Waldron Jul 8, 2024 8:55am
vaccine diversity flu covid shot needle

Moderna touts 3 phase 1 data sets to bolster early vax work

Mar 27, 2024 3:21pm
Gut stomach

Vaxart norovirus vaccine has mixed success in midphase test

Sep 7, 2023 5:31am
Stock imagegraphic of a page titled Norovirus with a stethoscope and oral pills in the frame

Vaxart's oral norovirus vax spurs immune response in ph. 2 trial

Jul 6, 2023 9:52am
Graphic images of staff members falling off a conveyor belt representing layoffs

Vaxart cans oral COVID-19 vaccine plans, lays off 27% of staff

Mar 16, 2023 6:15am
Publicly traded hotel companies beholden to Wall Street

Takeda spinout HilleVax hits Wall St., a test of choppy waters

Apr 7, 2022 10:48am